NYSE:JNJ 28 January 2026 - 7 February 2026

New York, Feb 7, 2026, 11:00 EST — The market has shut down for the day. Johnson & Johnson stock climbed 0.9% to finish Friday at $239.99, landing close to its intraday peak, after a New Jersey appeals court ejected a major plaintiffs’ firm from part of the company’s talc lawsuits. Roughly 8.3 million shares traded hands.

New York, Feb 6, 2026, 19:30 EST — After-hours Johnson & Johnson shares ticked up on Friday, holding steady into after-hours. Investors weighed a New Jersey court’s latest move in the company’s ongoing talc litigation, along with a new FDA safety notice tied to select devices.

New York, Feb 6, 2026, 12:50 EST — Regular session Johnson & Johnson shares inched higher on Friday, rising roughly 0.2% to $238.34 around midday, having peaked at $240.22 earlier. This kept the stock just above Thursday’s closing price of $237.79.

New York, Feb 5, 2026, 19:10 EST — After-hours Johnson & Johnson shares jumped about 1.4% Thursday, then held steady after hours. The move came as the company asked the U.S. Supreme Court to weigh in on whether a shareholder lawsuit accusing it of misleading statements about talc safety can move forward as a class action. The petition seeks clarification on the court’s 2021 Goldman Sachs ruling, focusing on how “price impact” — whether alleged falsehoods affected stock prices — factors into certifying investor groups. JNJ last changed hands at $237.79, after trading between $233.33 and $240.00 during regular hours.

New York, Feb 5, 2026, 14:05 EST — Regular session Johnson & Johnson shares climbed 1.3% to $237.59 in afternoon trading, pushing their recent gains further. The move came after the company petitioned the U.S. Supreme Court to review a shareholder lawsuit concerning claims about the safety of its talc products.

New York, Feb 3, 2026, 21:00 EST — The market has closed. Johnson & Johnson shares climbed roughly 1% on Tuesday following an upgrade from RBC Capital Markets, which lifted its price target and kept focus on the company’s ongoing legal issues. The stock last traded at $233.10, fluctuating between $230.00 and $235.24, with about 9.3 million shares changing hands.

New York, January 31, 2026, 10:29 EST — The market has closed. Johnson & Johnson shares edged down 3 cents to $227.25 on Friday after a U.S. judge dismissed a lawsuit accusing the company of fraud related to its talc bankruptcy approach. The plaintiffs claimed J&J employed a “Texas two-step,” moving talc liabilities into a subsidiary that filed for bankruptcy to stall cancer lawsuits. Judge Michael Shipp ruled they hadn’t proven any real harm caused by the delay. J&J’s litigation head Erik Haas slammed the claims as “wholly meritless,” while the plaintiffs’ attorney said they’re considering an appeal.

New York, Jan 30, 2026, 20:47 EST — Market closed Johnson & Johnson shares closed nearly flat Friday following Michael Shipp’s dismissal of a fraud lawsuit tied to the company’s failed talc-bankruptcy plan. The stock ended at $227.25, slipping just 0.01% after fluctuating between $225.34 and $228.40 throughout the session. Erik Haas labeled the allegations “wholly meritless,” while plaintiffs’ attorney Patricia Kipnis said she’s reviewing the ruling with clients to consider an appeal.

New York, Jan 30, 2026, 13:07 EST — Regular session Johnson & Johnson shares held steady in midday trading Friday after a U.S. judge threw out a lawsuit alleging the company committed fraud to route talc claims through bankruptcy. The company also announced that a European drug panel supported a wider label for its AKEEGA prostate cancer treatment.

New York, January 29, 2026, 21:37 EST — Market closed. Johnson & Johnson shares edged down 0.19% to close at $227.29 on Thursday. The drop came after a U.S. judge dismissed a fraud lawsuit targeting the company’s "Texas two-step" strategy, which involves moving talc liabilities into a subsidiary that then files for bankruptcy. U.S. District Judge Michael Shipp ruled the plaintiffs failed to prove they were harmed by the bankruptcy stays that paused cases from October 2021 through March 2025. J&J’s litigation head, Erik Haas, called the claims “wholly meritless.” During the session, the stock hit $230 and last changed hands at $227.98 in after-hours trading.

NEW YORK, Jan 29, 2026, 12:29 ET — Regular session Johnson & Johnson shares slipped 0.1% to $227.43 by midday Thursday, having peaked at $229.90 earlier. The stock had closed at $227.72 on Wednesday.

NEW YORK, January 28, 2026, 19:59 EST — After-hours Johnson & Johnson shares rose 1.5% on Wednesday, ending the session at $227.72. The jump came after Morgan Stanley upgraded the healthcare giant, highlighting strong momentum from its newer drug portfolio.

New York, Jan 28, 2026, 14:13 EST — Regular session Johnson & Johnson shares climbed Wednesday following U.S. regulators’ green light for a new combination use of its blood-cancer drug, Darzalex Faspro, expanding the treatment’s approved indications.